Diabetes is a common disease worldwide with a multitude of complications and high mortality. Moreover, its prevalence is increasing and many of our patients will have diabetes. We have known for almost 50 years that patients with diabetes undergo surgical procedures at a higher rate than patients who do not have the condition 1 and that they spend 45% longer in a hospital bed than patients with diabetes admitted to a medical ward.
Question
A 30-year-old patient with type 1 diabetes is listed for minor surgery. The ward doctor wants to commence the patient on an intravenous insulin 'sliding scale' to cover the patient while fasting. Is this really necessary?
The presence of diabetes as a co-morbidity to any admission is known significantly to increase length of stay 1 and to increase peri-operative mortality. 2 The reasons for this may include other co-morbidities but they are also influenced by control of blood glucose and the misuse of medication, parperi-operative care series ticularly insulin. The 2009 National Diabetes Inpatient Audit found that a quarter of patients on surgical wards experienced a hypoglycaemic event, potentially influencing mortality. 3 Conversely, high blood glucoses may affect wound healing and increase post-operative infections.
In 2011 NHS Diabetes published a detailed guide on the management of patients with diabetes undergoing surgery and elective procedures. 4 It is strongly recommended that healthcare professionals access this reference for more information. In this guide five common factors leading to adverse outcomes are identified (Table 1) .
Pre-operative care
There is evidence that good diabetes control pre-operatively, as measured by glycated haemoglobin, is associated with improved outcomes. 2 An upper limit of HbA1c of 8-9% is generally considered to be acceptable for surgery but the risks must be balanced against those for not proceeding with surgery. For many (particularly the elderly) these targets may not be achievable without unacceptable hypoglycaemia. A plan for the management of the patient's diabetes Detailed schemes for the management of patients' drugs/ insulins are available (Table 3 ) but locally agreed schemes should be in place.
Fluids
The choice of fluid is controversial but it is agreed that if an insulin infusion is in place, the intravenous fluid given simultaneously must contain glucose. However, the use of 5% dextrose is associated with an increased risk of hyponatraemia. The guidelines produced by NHS Diabetes recommend the use of 0.45% sodium chloride and 5% glucose with either 0.15% or 0.3% potassium chloride (as appropriate) 4 although it is recognised that this is not currently widely available. What is most important is that serum electrolytes are monitored regularly while a patient is receiving intravenous insulin and fluid. Ensure that an agreed and documented individual patient plan is communicated to all involved in the care pathway including:
• the patient (this should include written information on how to manage his or her insulin or other drugs and who to contact should the patient have any diabetes related problems.)
• relevant specialists (including anaesthetist, surgeon, diabetologist)
• staff in all relevant clinical areas Insulin pump therapy or other insulin regimes Encourage patient to self-manage. Contact the diabetes team for advice.
If unsure, seek advice from the diabetes team.
PERI-OPERATIvE CARE
Intra-operative care
The aim is to maintain blood glucose between 6mmol/l and 10mmol/l (acceptable 4-12mmol/l) and, if possible, avoid the unnecessary use of intravenous insulin infusions. Although insulin infusions are necessary in situations of prolonged fasting, their inappropriate use can be associated with considerable morbidity (Table 4 ). Capillary blood glucose should be checked prior to induction of anaesthesia and monitored at least hourly during anaesthesia. If an intravenous insulin infusion is being used, ensure appropriate fluid is being administered concomitantly. Anaesthetic techniques should be used that reduce the incidence of post-operative nausea and vomiting so that feeding can restart promptly.
Post-operative care
When the patient returns to the ward from theatre, it is important that there are clear written instructions for ward staff to manage the patient's diabetes, including any plan for stopping intravenous insulin infusions and restarting the patient's usual diabetes medication. Pain or nausea should be managed promptly to ensure an early return to eating and drinking.
Patients who usually self-manage their diabetes should be encouraged to do so. This includes glucose monitoring and the choice of the dose of bolus insulins around meals. Electrolytes should be monitored daily.
Newer drugs and surgery
In general there is less of a risk of hypoglycaemia with newer oral hypoglycaemics such as the meglitinides, dipeptidyl peptidase-4 antagonists and thiazolidinediones. Thiazolidinediones (also known as glitazones, eg pioglitazone) are associated with an increased risk of heart failure. Fluid balance should therefore be monitored closely in the postoperative period.
Data on the use of the newer injectable agents, glucagon-like peptide-1 agonists, during surgery are sadly lacking. Although the risk of hypoglycaemia is low, they do reduce gastric emptying. This is unlikely to be a problem with the shorter acting agents such as exenatide or liraglutide, which can be discontinued the day before planned surgery. A once weekly exenatide long acting release is also now available. Anaesthetists should be aware of a potential effect on gastric emptying pre-operatively.
How do you manage emergency surgery?
Blood glucose should be monitored closely and if it rises above 10mmol/l, a variable rate intravenous insulin infusion should be started until the patient is able to eat and drink.
How do you manage an elective evening operating list?
Many trusts are now introducing evening operating lists and these can lead to prolonged starvation for the patient. Evidence for this practice is currently lacking and diabetic patients should not be placed on evening lists when alternatives are available.
Can radio-opaque contrast be used with metformin?
Using contrast can lead to contrast induced nephropathy and pre-existing renal impairment in diabetic patients is a risk factor. Currently, there is no need to stop metformin after using contrast in patients with normal renal function.
Where should a diabetic patient be placed on the list?
One of the key aims in these patients is to minimise the starvation period and enable early resumption of normal diet and normal diabetic medication. It is recommended that patients are placed early on a list. For a morning list, this will enable patients to have lunch at the correct time and for an afternoon list, patients can have their evening meal at the normal time.
When should a variable rate intravenous insulin infusion be used? This is usually indicated in patients who are expected to miss two or more meals and therefore have a long period of starvation or in patients whose diabetic control is poor. An example of rates of infusion is given in Table 5 .
Table 4 Insulin infusions
The term 'variable rate intravenous insulin infusion' (VRIII) is now recommended to replace the term 'sliding scale' as the latter does not indicate by which route the insulin is given.
Problems include:
• Failure to monitor blood glucose regularly or to adjust the rate of insulin infusion, leading to hyper or hypoglycaemic incidents
• Administration of either insulin and/or glucose containing solutions without using an electronic infusion control device
• Incorrect setting of infusion pumps and syringe drivers leading to over or underinfusion of insulin and/or glucose • Severe hypoglycaemia (sometimes fatal) if glucose is discontinued but the insulin infusion is continued
• Stopping the VRII before usual insulin or diabetes medications are restarted. The half-life of insulin in the circulation is about 5-7 minutes and so it is imperative (particularly in type 1 patients) that basal insulin or usual oral hypoglycaemics are started before the insulin infusion is discontinued. Some experts recommend the continuation of long acting basal insulins such as detemir or glargine alongside the VRIII to facilitate the discontinuation of the intravenous insulin. Table 5 Insulin 
